Accreditation/Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 20.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Commercial SupportersThis activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Celgene Corporation, Genentech and Astellas, Lilly USA, LLC and Novartis Pharmaceuticals Corporation.
14th Annual International Lung Cancer Congress®
Hyatt Regency Huntington Beach
Huntington Beach, CA
July 25-27, 2013
The 14th Annual International Lung Cancer Congress® will provide current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies that will shape the future of lung cancer therapy.
Join leading international and national faculty as they address critical topics in lung cancer staging, personalized therapy, and the latest clinical data impacting the treatment of lung cancer. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management. A recurring session will also highlight clinical research activity of Cooperative Groups in the United States, Europe, and Asia.
Target AudienceThis educational activity is directed toward medical, surgical and radiation oncologists interested in the treatment of patients with lung cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers and other healthcare professionals interested in the treatment of lung cancer are also invited to attend.
Learning ObjectivesAt the conclusion of this activity, participants should be better prepared to:
- Determine correct tumor stage according to the 7th Edition of TNM lung cancer staging
- Select evidence-based therapeutic regimens in patients with early-stage and locally advanced NSCLC
- Formulate frontline and subsequent therapy for patients with metastatic NSCLC based on biomarker status and patient/tumor characteristics
- Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen
- Outline current therapeutic approaches for patients with SCLC and mesothelioma
- Evaluate data on new agents and approaches in development for lung cancer
- Recommend appropriate patients with lung cancer for clinical trial enrollment
- State of the Art: Multimodality Therapy
- Surgical Approaches to Locally Advanced NSCLC
- Optimizing the Dose and Schedule of Radiation Therapy in Stage III NSCLC
- Integration of Targeted Agents Into Combined Modality Therapy for NSCLC
- State-of-the-Art Treatment of Advanced Lung Cancer
- Antiangiogenic Agents
- ALK Inhibitors
- c-Met Inhibitors
- Immunotherapy in Lung Cancer
- HSP90 as a Therapeutic Target
- Incorporating Next-Generation Sequencing for Molecular Profiling: Future Implications for Treatment
- Tumor Board Reviews
- Poster Discussions
- Sixth Annual Addario Foundation Keynote Lecture
PER® has chosen to partner with the International Association for the Study of Lung Cancer (IASLC) and the Bonnie J. Addario Lung Cancer Foundation (BJALCF) for the 14th Annual International Lung Cancer Congress®.
IASLC is the only global organization dedicated to the study of lung cancer. Founded in 1972, the association's membership includes more than 3,000 lung cancer specialists in 80 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public.
BJALCF is the first international collaborative entity of its kind, raising over $6 million for Lung Cancer research. BJALCF’s focus is on projects promising progress through early detection, genetic testing, and drug discovery with patient-focused outcomes. Their ultimate goal is to increase the low survival rate of lung cancer by becoming the largest source of non-profit funding dedicated to turning lung cancer into a manageable chronic disease. Since 2008, BJALCF has sponsored a key-note address and provided overall support of the International Lung Cancer Congress.
Disclosure Policy and Conflict of Interest ResolutionAs a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest (COI).
Additionally, PER® is required by ACCME to resolve all COI. We have identified and resolved all COI prior to the start of this activity by using a multi-step process.
Alex A. Adjei, MD, PhD, FACP; Hisao Asamura, MD; Paul Baas, MD, PhD; Walter J. Curran, Jr., MD; Laurie Gaspar, MD; Dominique Grunenwald, MD, PhD; Philip C. Mack, PhD; Silvia Novello, MD, PhD; Keunchil Park, MD, PhD; Jill M. Siegfried, PhD; Rolf A. Stahel, MD; Stephen G. Swisher, MD, FACS.
The following individuals have relevant financial relationships with commercial interests to disclose:
Paul Bunn, Jr., MD – Consultant/Ad Board-- Amgen Inc., Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim Pharmaceuticals, Inc., Celgene Corporation, Daiichi Sankyo Company Ltd, Eisai Inc., GlaxoSmithKline, Lilly USA, LLC, Merck & Co., Inc., Merck Serono, Merrimack Pharmaceuticals, Inc., Myriad Genetics, Pfizer, Inc., Roche/Genentech, sanofi-aventis U.S. LLC, Synta Pharmaceuticals –Stock/Shareholder – Merrimack Pharmaceuticals, Inc.; David P. Carbone, MD, PhD – Consultant – Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, Genentech, Amgen Inc., Biodesix, Boehringer Ingelheim Pharmaceuticals, Inc., EMD Serono, Inc., Celgene Corporation; Hak Choy, MD – Grant/Research Support – Celgene Corporation, Consultant – EMD Serono, Inc., Bayer Corporation; David R. Gandara, MD – Consultant/Advisory Board – Amgen Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb/ImClone, Celgene Corporation, GlaxoSmithKline, Genentech, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc., sanofi-aventis U.S. LLC, Synta Pharmaceuticals, Response Genetics, Inc. – Research Support – Abbott Laboratories, Bristol-Myers Squibb/ImClone, Genentech, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer, Inc.; Roy S. Herbst, MD, PhD – Consultant – N-of-One®, Inc., DiaTech Oncology, Astellas, Biothera, Quintiles Inc., Lilly USA, LLC – Grant/Research Support – Genentech; Fred R. Hirsch, MD, PhD – Grant/Research Support – Ventana Medical Systems, Inc., Celgene Corporation, Genentech, ImClone, Lilly USA, LLC (all through the University of Colorado) – Consultant – Boerhinger Ingelheim Pharmaceuticals Corporation, Pfizer, Inc., Genentech, Bristol-Myers Squibb, Lilly USA, LLC; Glenwood D. Goss, MD, BCh, FCP(SA), FRCPC – Grant/Research Support – Roche, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Pfizer, Inc. – Honoraria for Advisory Boards – Roche, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Pfizer, Inc.; Karen Kelly, MD – Consultant – EMD Serono, Inc., Synta Pharmaceuticals, Daiichi Sankyo Company Ltd, Boerhinger Ingelheim Pharmaceuticals Corporation; Corey J. Langer, MD, FACP – Grant/Research Support – GlaxoSmithKline, Genentech (Roche) – Scientific Advisor – Bristol-Myers Squibb, Genentech (Roche), Lilly USA, LLC, Bayer/Onyx, Abraxis (Celgene), Abbott Laboratories, Biodesix, Boehringer Ingelheim Pharmaceuticals, Inc., Synta Pharmaceuticals; Primo Lara, Jr., MD - Grant/Research Support – Exelixis, Inc., Genentech, Janssen Pharmaceuticals, Inc., OncoGenex Pharmaceuticals Inc., Polaris Health Directions, Genentech (Roche) – Consultant – AVEO Pharmaceuticals, Inc., Exelixis, Inc., ImmunoGen, Inc., Janssen Pharmaceuticals, Inc., Medivation, Inc./Astellas – Other Support – Elsevier Inc. (Editorial Board); Tianhong Li, MD, PhD – Grant/Research Support – Astellas, Lilly USA, LLC – Consultant – Biodesix; Rogerio C. Lilenbaum, MD – Consultant – Genentech; Tetsuya Mitsudomi, MD, PhD - Grant/Research Support – AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Chugai Pharma USA LLC, Pfizer, Inc., Taiho Pharmaceutical Co., Ltd., Lilly USA, LLC – Consultant - Chugai Pharma USA LLC, Roche, Pfizer, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Synta Pharmaceuticals, Novartis Pharmaceuticals Corporation, GlaxoSmithKline – Speaker Bureau - AstraZeneca, Pfizer, Inc., Chugai Pharma USA LLC, Lilly USA, LLC, Boehringer Ingelheim Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd.; Tony Mok, MD - Grant/Research Support – AstraZeneca – Consultant – AstraZeneca, Roche, Lilly USA, LLC, Merck Serono, Eisai Inc., Bristol-Myers Squibb, BeiGene, Ltd., Pfizer, Inc., AVEO Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline – Speakers Bureau – AstraZeneca, Roche, Lilly USA, LLC, Merck Serono, Pfizer, Inc.; Vassiliki Papadimitrakopoulou, MD – Other Support – AstraZeneca, Bayer/Onyx, Bristol-Myers Squibb, Merck & Co., Inc., Pfizer, Inc., Novartis Pharmaceuticals Corporation, Astellas; Harvey I. Pass MD – Grant/Research Support – NIH National Cancer Institute; US Department of Defense, Centers for Disease Control, Belluck and Fox LLP, Levi, Phillips, Konigsberg, SomaLogic – Consultant – Champions Oncology Inc. – Other Support –- Patents for osteopontin, microRNAs; NIH licensing of Cell Lines; Giorgio V. Scagliotti, MD, PhD – Speakers Bureau – Lilly USA, LLC, Roche, AstraZeneca, Pfizer, Inc.; Everett E. Vokes, MD – Consultant – Amgen Inc., AVEO Pharmaceuticals, Inc., Biodesix, Boehringer Ingelheim Pharmaceuticals, Inc., MethylGene, Millennium Pharmaceuticals, Inc., sanofi-aventis U.S. LLC; Heather A. Wakelee, MD – Grant/Research Support – Genentech/Roche, Lilly USA, LLC, Novartis Pharmaceuticals Corporation, Exelixis, Inc., Clovis Oncology , AstraZeneca, Merck & Co., Inc., Agennix AG, Pfizer, Inc., Celgene Corporation, ArQule, Regeneron Pharmaceuticals, Inc. – Consultant – Gilead; Ken Y. Yoneda, MD -- Consultant – Boehringer Ingelheim Pharmaceuticals, Inc., Pfizer, Inc. – Speakers Bureau – Boston Scientific.
Off-Label Disclosure and DisclaimerThis CME activity will include discussions of investigational, unapproved, or off-label use of drugs including but not limited to LDK 378, APZ26113, CH5424802, C01686, AZ209291 for ALK and EGFR resistance, and ABT888, fulvestrant, C225 in LA-NSCLC, BLP-25 in LA-NSCLC, and docetaxel. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this CME activity.
You must be logged in to PER to register for this meeting
Or Register for PER now